Key result
Immediate implementation of preventive stroke therapy, including antiplatelets for non-cardioembolic stroke and anticoagulation for cardiac sources, is highly effective for secondary prevention.
Why the study?
Does medical secondary stroke prevention reduce recurrent cerebrovascular events in patients with TIA and minor stroke?
Systematic Review
Does medical secondary stroke prevention reduce recurrent cerebrovascular events in patients with TIA and minor stroke?
Immediate implementation of targeted preventive stroke therapy, including specific antiplatelets or anticoagulants based on etiology and aggressive risk factor management, is crucial for secondary stroke prevention in TIA and minor stroke patients.
Prompt antithrombotic therapy by etiology reduces recurrence after TIA or minor stroke; reinforces current secondary prevention guidelines with Level 1 evidence.
BACKGROUND: Secondary stroke prevention after transient ischemic stroke (TIA) or minor stroke is of major importance in order to avoid recurrent cerebrovascular events and decrease morbidity and mortality. OBJECTIVE/METHODS: Systematically review of recently published, high-quality studies emphasizing the need for emergency assessment and treatment of patients with TIA and minor stroke and to give a comprehensive and distinct overview over medical secondary stroke prevention trials performed in these patients. RESULTS/CONCLUSIONS: Evaluation and implementation of preventive stroke therapy has to be immediate in patients with TIA and stroke. For patients with non-cardioembolic stroke, antiplatelet agents are the treatment of choice. Aspirin plus extended-release dipyridamole and clopidogrel are more effective than aspirin and should be used in patients with a high risk of recurrent stroke. Oral anticoagulation is highly effective in patients with a cardiac source of embolism. Treatment of risk factors such as arterial hypertension and high cholesterol is even more important in secondary stroke prevention than in primary prevention. Vitamin supplementation and lowering of elevated levels of homocysteine are not effective in stroke prevention.
No takes yet. Share an insight, caveat, or question.
Weber et al. (2009) conducted a systematic review in TIA and minor stroke. Medical secondary stroke prevention therapies was evaluated on Recurrent cerebrovascular events. Immediate implementation of preventive stroke therapy, including antiplatelets for non-cardioembolic stroke and anticoagulation for cardiac sources, is highly effective for secondary prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: